Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Critical Path Opportunities List Previewed By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.

You may also be interested in...



FDA To Provide Updates On Agency Involvement In Critical Path Projects

Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.

FDA To Provide Updates On Agency Involvement In Critical Path Projects

Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.

CDER Reorganization Will Create Center-Level Associate Director For Safety

Proposed realignment also will include a new office to serve as a nexus for FDA's Critical Path initiatives.

Related Content

Topics

UsernamePublicRestriction

Register

PS061332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel